Authorities File Bribery Charges Against Senior Officials Of Pharma Company And SFDA
This article was originally published in PharmAsia News
Executive Summary
Chen Haifeng, head of China's State FDA's Center for Drug Evaluation and Gu Lijun, pharma company general manager, were taken to court for alleged bribery and corruption to the tune of RMB 1.3 million between 2004-2007 for fast drug registration approvals
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.